Record Q4 net revenues up 53.1% YoY to $211.4mln, raises FY23 guidance.

• Biotech firm reports record Q1 net revenues of $211.4mln, up 53.1% YoY. • Rare disease revenues hit $104mln, up 66% YoY. • Generics revenues up 22.1% YoY to $90.3mln. • Adjusted EBITDA hits record $54.1mln, up 62.8% YoY. • Diluted GAAP EPS at $0.36, adjusted EPS at $1.80. • 2025 guidance increased, with net revenues expected to reach $818-$843mln.

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) reported record-breaking financial results for the second quarter ended June 30, 2025. The company's total net revenues for the quarter reached $211.4 million, representing a year-over-year (YoY) growth of 53.1% on a reported basis and 37.0% on an organic basis. This impressive performance was driven by strong growth across all business units, including Rare Disease and Generics.

Rare Disease revenues hit $104.0 million, marking a significant 66.0% YoY increase. This growth was primarily driven by the continued success of Cortrophin Gel, which saw a 66.0% increase in net revenues to $81.6 million. ILUVIEN and YUTIQ contributed $22.3 million in net revenues, in line with expectations. The company also reported a record quarterly adjusted non-GAAP EBITDA of $54.1 million, up 62.8% YoY.

Generics revenues increased 22.1% YoY to $90.3 million, driven by new product launches and strong operational execution. The company's gross margin improved from 58.2% to 64.7% on a GAAP basis and from 58.4% to 64.9% on a non-GAAP basis, primarily due to favorable mix toward Rare Disease products and the positive impact of the prucalopride launch.

ANI Pharmaceuticals also reported diluted GAAP earnings per share (EPS) of $0.36 and adjusted non-GAAP diluted EPS of $1.80 for the quarter. The company increased its 2025 guidance, with expected net revenues ranging from $818.0 million to $843.0 million, adjusted non-GAAP EBITDA of $213.0 million to $223.0 million, and adjusted non-GAAP diluted EPS of $6.98 to $7.35.

President and CEO Nikhil Lalwani commented, "We had another record-setting quarter for our Company, with all-time highs in net revenue, adjusted EBITDA, and adjusted EPS, reflecting very strong momentum across our business units."

References:
[1] https://www.globenewswire.com/news-release/2025/08/08/3130046/0/en/ANI-Pharmaceuticals-Reports-Record-Second-Quarter-2025-Financial-Results-and-Raises-2025-Guidance.html